Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Recursion Pharmaceuticals, Inc.’s reported figures.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
FAQ
- What is Recursion Pharmaceuticals, Inc.'s EBITDA?
- Recursion Pharmaceuticals, Inc. (RXRX) reported EBITDA of -$116.8M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s EBITDA changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s EBITDA increased by 23.3% year-over-year, from -$152.38M to -$116.8M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s EBITDA has grown at a 34.1% compound annual growth rate (CAGR), from -$174.37M to -$564.43M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Recursion Pharmaceuticals, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude